Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects:

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Patient characteristics before and after propensity score matching. by Anna D. Ware (19688153)

Subjects:

Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute th... by Anna D. Ware (19688153)

Subjects:

Forest plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disor... by Anna D. Ware (19688153)

Subjects:

Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date. by Anna D. Ware (19688153)

Subjects:

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

“…A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”

S1 File - by Michael Gulledge (20577135)

“…Despite the prevalence and severity of sleep disturbances during opioid withdrawal, there is a gap in our understanding of their interactions. …”

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

SHAP dependence plots with interaction coloring. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

Screening process diagram. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

SHAP waterfall plot. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

SHAP decision plot. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

LASSO regression visualization plot. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

SHAP dependence plots. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”

Tertile stratified subgroup analysis. by Wentao Yang (205781)

“…This study examines the eGDR-frailty link, develops a machine learning predictive model to address this gap, and explores diabetes mellitus (DM) as a mediator, providing new insights for clinical intervention.…”